USA — In a groundbreaking effort to combat the rising rates of sexually transmitted infections (STIs), a new form of post-exposure prophylaxis (PEP) has emerged, leveraging the widely available and inexpensive antibiotic, doxycycline.
Known as doxy-PEP, this preventative treatment offers hope in extinguishing STIs before they cause symptoms or spread to others, specifically targeting three common bacterial STIs: chlamydia, gonorrhea, and syphilis.
Promising research findings indicate that doxy-PEP can substantially lower the risk of contracting these infections.
With this encouraging data, the Centers for Disease Control and Prevention (CDC) plans to issue guidance to healthcare providers and public health departments, offering a roadmap for implementing this novel approach.
Dr. Edward Hook, a professor of medicine and epidemiology at the University of Alabama, Birmingham, emphasizes the urgency for innovative solutions, stating, “Our efforts to control STIs for the last 50 years have not succeeded. It’s time to do something different.”
Promising results from clinical trials
The research on doxy-PEP has primarily focused on gay and bisexual men and transgender women, who are at higher risk of STIs.
Dr. Annie Luetkemeyer, a professor of medicine and infectious diseases at the University of California, San Francisco, led a clinical trial on doxy-PEP and reported consistent reductions in STIs among the participants.
The study, published in the New England Journal of Medicine, showed an impressive 65% overall reduction in new STIs among individuals who took doxycycline within 24 to 72 hours after condomless sex.
The trial demonstrated an approximate 80% reduction in new chlamydia cases and over 50% reduction in gonorrhea cases.
Additionally, while fewer syphilis cases were reported in the trial, doxy-PEP was found to be effective in reducing syphilis infections as well.
Dr. Leandro Mena, director of the CDC’s Division of STD Prevention, lauds the strong evidence supporting doxy-PEP and stresses the need for additional tools in the fight against bacterial STIs.
Other research suggests that prescribing doxycycline for 12 months to patients with an STI diagnosis could potentially reduce future infections by more than 40%.
Limitations and antibiotic resistance concerns
While doxy-PEP shows great promise for certain groups, its effectiveness for most women remains uncertain.
A trial involving over 400 Kenyan women at high risk of STIs found no reductions in infections, leading to disappointment among researchers seeking solutions for this demographic.
Another concern related to doxy-PEP is its potential contribution to antibiotic resistance, which poses a global crisis.
Researchers have begun monitoring antimicrobial resistance among those receiving the treatment. There has been an 8% increase in resistance levels to doxycycline for Staphylococcus aureus, a bacteria found on the nose and skin.
However, the trajectory of resistance over time and its impact on public health need further investigation.
Gonorrhea, a common and concerning STI due to its resistance-prone nature, is already showing resistance to the class of antibiotics that includes doxycycline.
Despite this, experts argue that the meaningful reduction in gonorrhea through doxy-PEP should not be dismissed, as it could still offer substantial public health benefits.
Moving forward with Doxy-PEP
As the CDC prepares to issue guidance on doxy-PEP, it is expected to focus on offering the treatment to gay and bisexual men and transgender women, the groups included in the U.S. and European clinical trials.
However, there are discussions about extending access to other individuals at higher risk of STIs, irrespective of sexual orientation.
While the potential for antibiotic resistance raises concerns, using doxy-PEP presents a valuable public health intervention.
For many individuals, the choice is not between antibiotics and no antibiotics, as they may require treatment for STIs at some point regardless.
Implementing doxy-PEP offers a promising line of attack in curbing the spread of STIs and brings hope for a future with reduced infection rates and improved sexual health for vulnerable populations.
Nonetheless, further research and monitoring are vital to ensure the treatment’s efficacy and safety as it becomes an integral part of the fight against STIs.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
